Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Upper Extremity Deep Vein Thrombosis in Cancer Patients: Clinical Course by Cancer Site.

JACC. CardioOncology·2026
Same author

Peripartum Vascular Calamities: Placental Abruption and Amniotic Fluid Emboli.

Seminars in thrombosis and hemostasis·2026
Same author

Outcomes and predictors of complications after distal deep vein thrombosis: a prospective analysis of 8488 patients.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Maximizing photon utilization in spectroscopic single-molecule localization microscopy using symmetrically dispersed dual-wedge prisms.

Npj imaging·2026
Same author

Platelet and Fibrinogen Dynamics After CAR-T Cell Therapy in Relapsed/Refractory B-Cell Lymphoma May Predict ICANS Onset.

European journal of haematology·2026
Same author

Challenges in Balancing Hemostasis and Thrombosis in Therapy Tailoring for Hemophilia: A Narrative Review.

International journal of molecular sciences·2026
Same journal

[Tennis Elbow Among Players].

Harefuah·2026
Same journal

[Internal Medicine - My Mission].

Harefuah·2026
Same journal

[Treatment of Morbid Obesity in Israel: GLP-1 Agonists Versus Bariatric Surgery - Clinical and Economic Aspects].

Harefuah·2026
Same journal

[Baby steps: Post-operative Treatment Recommendations for Pediatric Tracheostomy in Israel].

Harefuah·2026
Same journal

[Mastoiditis Caused by Fusobacterium Necrophorum: an Unusual Pathogen in a Well-Known Disease].

Harefuah·2026
Same journal

[Cochlear Implantation in Single-Sided Deafness - Six Years of Follow-Up from Diagnosis and Consistent Use, Through Dedicated and Creative Auditory Learning, to the Development of Bilateral Central Processing Abilities].

Harefuah·2026
See all related articles

Related Experiment Video

Updated: Jun 8, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

[Warfarin therapy and hemarthrosis].

Amir Kuperman1, Benjamin Brenner

  • 1Thrombosis and Hemostasis Unit, Rambam Health Care Campus, Haifa. amir.kuperman@naharia.health.gov.il

Harefuah
|October 9, 2010
PubMed
Summary
This summary is machine-generated.

Bleeding complications like knee joint bleeding (hemarthrosis) can occur in patients taking warfarin. This case report highlights hemarthrosis in a patient with multiple clotting disorders on warfarin therapy.

More Related Videos

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

Related Experiment Videos

Last Updated: Jun 8, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

Area of Science:

  • Internal Medicine
  • Hematology
  • Rheumatology

Background:

  • Oral anticoagulants, such as warfarin, are crucial for managing thromboembolic disorders.
  • While bleeding is a known risk, specific joint bleeding (hemarthrosis) is rare in patients on anticoagulant therapy.
  • Congenital thrombophilia and Behcet's disease are complex conditions requiring careful anticoagulation management.

Observation:

  • This case report details a patient with a history of recurrent venous and arterial thromboembolism, congenital thrombophilia, and Behcet's disease.
  • The patient was undergoing treatment with warfarin for their thromboembolic conditions.
  • The patient developed hemarthrosis, specifically affecting the knee joint, while on warfarin therapy.

Findings:

  • Hemarthrosis is an infrequent but significant bleeding complication in patients receiving oral anticoagulant treatment.
  • The occurrence of knee hemarthrosis in this patient underscores the potential risks even with careful monitoring.
  • This case necessitates a review of literature and discussion on managing hemarthrosis in anticoagulated patients with complex comorbidities.

Implications:

  • Clinicians should maintain a high index of suspicion for hemarthrosis in patients on warfarin, particularly those with underlying thrombotic or inflammatory conditions.
  • Optimal anticoagulation strategies and bleeding risk mitigation are critical in patients with combined thrombophilia and Behcet's disease.
  • Further research may be warranted to elucidate the specific mechanisms and optimal management of hemarthrosis in this patient population.